Key Takeaways
- Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist, while Ozempic (semaglutide) activates only the GLP-1 receptor — this mechanistic difference is the main reason Mounjaro tends to produce greater average weight loss in head-to-head trial data.
- In the SURMOUNT-1 trial, tirzepatide 15 mg produced approximately 22.5% average body weight loss over 72 weeks, compared to roughly 15-16% with semaglutide 2.4 mg in the STEP trial programme.
- A consultation at DCDC starts from AED 299, with same-day on-site blood work and DEXA body composition scanning available to establish a metabolic baseline before starting either medication.
- Both medications share a similar gastrointestinal side effect profile — nausea, vomiting, diarrhoea, and constipation — though incidence and severity vary by individual, dose, and titration speed.
- Neither Mounjaro nor Ozempic is a substitute for lifestyle change. Both were studied alongside a reduced-calorie diet and increased physical activity, and results depend on maintaining those habits.
- Insurance coverage for either drug in the UAE depends heavily on diagnosis — type 2 diabetes claims are approved far more consistently than weight-management claims — so verifying coverage before starting treatment matters.
- Choosing between Mounjaro and Ozempic should be a shared medical decision based on BMI, comorbidities, prior GLP-1 response, and personal goals, not on which name is trending on social media.
Demand for GLP-1 weight loss medications in the UAE has surged, and the mounjaro vs ozempic question is now one of the most common conversations happening in Dubai consultation rooms. Both are once-weekly injectable medications that can produce significant, medically supervised weight loss, yet they work through different mechanisms, are dosed differently, and are backed by different clinical trial programmes. At DCDC's Endocrine and Metabolic Disorders clinic in Dubai Healthcare City, patients frequently arrive having already researched both drugs online and want a clear, evidence-based comparison before deciding. This guide lays out exactly how Mounjaro and Ozempic differ — and where they overlap — so you can have an informed conversation with your doctor.
GLP-1 receptor agonists have moved from a niche diabetes treatment to a mainstream part of Dubai's weight management landscape in just a few years. Mounjaro (tirzepatide) and Ozempic (semaglutide) are the two most frequently discussed options, but they are not interchangeable. Below, we compare them across mechanism, dosing, clinical trial outcomes, side effects, cost in Dubai, and insurance coverage, and outline exactly what a supervised treatment pathway looks like at DCDC.
Health Screening Packages
Save with our bundled screening packages — specialist consultation included
Mounjaro vs Ozempic at a Glance: Side-by-Side Comparison
Before the detail, here is a side-by-side summary of the key differences between Mounjaro and Ozempic. Mounjaro is manufactured by Eli Lilly and Ozempic by Novo Nordisk; the two medications belong to the same broad drug class but are chemically distinct compounds.
| Feature | Mounjaro | Ozempic |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Mechanism of action | Dual GIP/GLP-1 receptor agonist | GLP-1 receptor agonist only |
| FDA-approved indication | Type 2 diabetes mellitus | Type 2 diabetes mellitus |
| Weight-loss-specific sibling | Zepbound (same molecule) | Wegovy (same molecule) |
| Dose range | 2.5 mg to 15 mg weekly | 0.25 mg to 2 mg weekly |
| Key clinical trial programme | SURMOUNT | STEP |
| Average weight loss (highest dose) | ~22.5% of body weight (72 weeks) | ~15-16% of body weight (68 weeks) |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Monthly cost in Dubai | AED 1,200-2,200 | AED 800-1,500 |
| UAE availability | Widely available since 2023 | Widely available since 2018 |
Mounjaro vs Ozempic comparison table (2026)
The headline distinction is mechanism: Mounjaro targets two hormone receptors instead of one, and this dual action is associated with greater average weight loss in trial populations. However, greater average weight loss does not automatically mean a better fit for every patient — dosing tolerance, side effects, cost, and insurance status all factor into the right choice.
How Mounjaro Works: A Dual GIP/GLP-1 Agonist
Mounjaro (tirzepatide) was approved by the US Food and Drug Administration (FDA) in May 2022 for the treatment of type 2 diabetes mellitus. What sets it apart pharmacologically is that it activates two separate incretin hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 (glucagon-like peptide-1) receptor. Both hormones are released naturally by the gut after eating, and both play a role in insulin secretion, appetite regulation, and gastric emptying.
By engaging both receptor pathways simultaneously, tirzepatide produces a stronger combined effect on appetite suppression, satiety signalling, and blood sugar control than a GLP-1-only medication typically achieves. Mounjaro is available in six dose strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg — allowing for a gradual, individualised titration that many patients tolerate well despite the medication's greater potency.
How Ozempic Works: GLP-1 Receptor Agonist Only
Ozempic (semaglutide) was approved by the FDA in December 2017, also for type 2 diabetes. It works by mimicking the single GLP-1 hormone, binding to GLP-1 receptors to stimulate glucose-dependent insulin release, suppress glucagon secretion, slow gastric emptying so food stays in the stomach longer, and act on appetite centres in the brain to reduce hunger and increase satiety. Because it engages only one of the two incretin pathways that tirzepatide targets, its metabolic and appetite-suppressing effects are generally somewhat less pronounced at an equivalent point in dose titration.
Ozempic is dosed from 0.25 mg up to a maximum of 2 mg weekly. It remains one of the most extensively studied and prescribed GLP-1 medications worldwide, with more than eight years of real-world safety data supporting its use. Semaglutide's weight-loss-specific formulation, marketed as Wegovy at a higher 2.4 mg dose, is covered in detail in our Ozempic vs Wegovy comparison, which is useful background if you are also weighing semaglutide's own two product lines against Mounjaro.
Weight Loss Results Compared: SURMOUNT vs STEP Trials
The most reliable way to compare Mounjaro and Ozempic is through their respective clinical trial programmes, since no large trial has directly randomised patients to one drug versus the other head-to-head at matched maximum doses.
Mounjaro: SURMOUNT Trial Results
The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, enrolled 2,539 adults with obesity or overweight and at least one weight-related complication, without diabetes. Over 72 weeks, participants on tirzepatide 15 mg lost an average of 22.5% of body weight, those on 10 mg lost 21.4%, and those on 5 mg lost 15.0%, compared to 2.4% in the placebo group. More than half of participants on the highest dose lost 20% or more of their body weight, a result not previously seen with a pharmacological weight loss treatment. SURMOUNT-2, which enrolled participants with type 2 diabetes, showed a somewhat lower but still substantial 12.8-14.7% weight loss, reflecting the more treatment-resistant nature of weight loss in diabetic patients.
Ozempic: STEP Trial Results
The STEP (Semaglutide Treatment Effect in People with Obesity) trial programme measured semaglutide 2.4 mg (the Wegovy dose) rather than Ozempic's lower 2 mg ceiling, but this remains the most relevant comparison for maximum semaglutide efficacy. In STEP 1, participants without diabetes lost an average of 14.9% of body weight over 68 weeks, versus 2.4% with placebo. At Ozempic's own approved diabetes-focused dose of 1 mg, the SUSTAIN trial programme showed a more modest 4.5-6.5 kg average weight loss, since that programme's primary endpoint was blood sugar control rather than maximum weight reduction.
Taken together, the trial evidence suggests tirzepatide produces roughly 6-8 percentage points more average weight loss than semaglutide 2.4 mg, and considerably more than semaglutide at Ozempic's standard diabetes doses. This is consistent with the SURMOUNT-5 trial, one of the few studies to directly compare tirzepatide against semaglutide 2.4 mg in the same population, which found tirzepatide produced significantly greater weight loss over 72 weeks.
Dosing and Administration Differences
Both medications are self-administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm, using a pre-filled pen. The dosing philosophy differs meaningfully between them.
Mounjaro Dosing Schedule
- Weeks 1-4: 2.5 mg weekly (initiation dose, not intended for glycaemic or weight-loss effect)
- Weeks 5-8: 5 mg weekly (first therapeutic dose)
- Every 4 weeks thereafter: Increase in 2.5 mg increments as tolerated, up to 15 mg
- Maintenance: Most patients reach a stable maintenance dose between 5 mg and 15 mg depending on response and tolerability
Ozempic Dosing Schedule
- Weeks 1-4: 0.25 mg weekly (initiation dose, not for glycaemic control)
- Weeks 5-8: 0.5 mg weekly (first therapeutic dose)
- Week 9 onward: 1 mg weekly (standard maintenance dose)
- Optional: 2 mg weekly if additional glycaemic or weight benefit is needed
Mounjaro's six available dose strengths give physicians more granular control over titration, which can help minimise gastrointestinal side effects while still reaching a clinically effective dose. Ozempic's four dose strengths are simpler but offer a wider percentage jump between steps, which is one reason some patients tolerate the Mounjaro titration schedule slightly better.
Side Effects Comparison: Mounjaro vs Ozempic
Because both drugs act on the GLP-1 pathway, their side effect profiles overlap substantially. Mounjaro's additional GIP activity does not introduce a fundamentally different category of side effects, but trial data shows some differences in frequency.
| Side Effect | Mounjaro (tirzepatide) | Ozempic (semaglutide) |
|---|---|---|
| Nausea | ~18-31% (dose-dependent) | ~15-20% (higher at Wegovy dose ~44%) |
| Diarrhoea | ~12-23% | ~8-15% |
| Vomiting | ~6-13% | ~5-9% |
| Constipation | ~6-17% | ~5-11% |
| Injection site reactions | Mild, uncommon | Mild, uncommon |
| Decreased appetite | ~11-27% | ~9-11% |
Reported side effect incidence ranges from SURMOUNT and SUSTAIN/STEP trial data (2026)
Serious Risks (Both Medications)
- Thyroid C-cell tumours (boxed warning): Both tirzepatide and semaglutide caused thyroid tumours in rodent studies. Neither has confirmed this risk in humans, but both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
- Pancreatitis: Rare but serious for both drugs. Persistent severe abdominal pain radiating to the back requires immediate medical attention.
- Gallbladder problems: Rapid weight loss from any cause increases gallstone risk; this may be more relevant with Mounjaro given its typically greater average weight loss.
- Acute kidney injury: Reported in patients with severe dehydration secondary to gastrointestinal side effects. Adequate fluid intake is essential on either medication.
- Hypoglycaemia: Low blood sugar risk increases when either drug is combined with insulin or sulfonylureas, requiring dose adjustment of those other medications.
In practice, most patients experience side effects that are worst during the first few weeks of a dose increase and settle within days to a couple of weeks. Slower titration, smaller meal portions, and adequate hydration meaningfully reduce symptom severity on both medications. For a broader look at semaglutide-specific dosing and side effect management, see our Ozempic weight loss guide.
Cost Comparison in Dubai
Cost is one of the deciding factors for many patients choosing between Mounjaro and Ozempic in Dubai. Mounjaro's medication price is generally higher than Ozempic's, reflecting its newer patent status and dual-mechanism formulation.
| Cost Component | Mounjaro | Ozempic |
|---|---|---|
| Monthly medication cost | AED 1,200-2,200 | AED 800-1,500 |
| Initial consultation at DCDC | From AED 299 | From AED 299 |
| Metabolic blood panel | From AED 399 | From AED 399 |
| DEXA body composition scan | From AED 400 | From AED 400 |
| Monthly follow-up visit | From AED 299 | From AED 299 |
| Typical insurance coverage likelihood | Moderate (diabetes indication) | Higher (longer-established diabetes indication) |
Cost comparison: Mounjaro vs Ozempic in Dubai (2026)
While Mounjaro carries a higher sticker price per month, some patients reach their weight goals in fewer total months of treatment given its stronger average effect, which can partially offset the higher per-month cost over a full treatment course. DCDC works with over 20 insurance providers including Daman, AXA, and Bupa, offering direct billing so eligible patients are not required to pay upfront and claim reimbursement separately.
Not Sure Which GLP-1 Medication Is Right for You?
Book a consultation at DCDC from AED 299. We assess your metabolic profile, run same-day blood work in our on-site laboratory, and recommend the best treatment plan for your goals.
MOHAP-licensed clinic in Dubai Healthcare City. Free parking available.
Who Is a Better Candidate for Mounjaro vs Ozempic?
There is no universal answer to which drug is better — the right choice depends on individual metabolic profile, prior treatment history, and personal goals. A thorough pre-treatment workup, including fasting insulin and glucose testing to check for underlying insulin resistance, helps a physician match the medication to the patient rather than the other way around.
Mounjaro May Be the Better Choice If:
- You have a higher BMI and are seeking the maximum possible average weight loss supported by current trial data
- You have type 2 diabetes with significant insulin resistance, where the dual GIP/GLP-1 mechanism may offer additional glycaemic benefit
- You have tried semaglutide at its maximum tolerated dose without reaching your target weight loss
- You can tolerate a higher monthly medication cost and do not have insurance restrictions favouring a specific brand
Ozempic May Be the Better Choice If:
- You have type 2 diabetes and your insurance plan has an established, well-documented approval pathway for semaglutide
- You prefer a medication with a longer real-world safety track record (semaglutide has been used since 2017, versus tirzepatide since 2022)
- Your target weight loss is more modest and does not require the maximum possible efficacy
- You want a lower starting monthly cost while achieving clinically meaningful weight loss
In many cases, patients are good candidates for either medication, and the deciding factor becomes cost, insurance coverage, or simply which titration schedule and side effect pattern they tolerate better in the first few months.
Insurance Coverage for GLP-1 Medications in the UAE
Insurance coverage in Dubai for both Mounjaro and Ozempic depends primarily on the diagnosis being treated rather than the specific drug. Patients with a confirmed type 2 diabetes diagnosis generally have a much easier path to coverage than patients seeking either medication purely for weight management, which most UAE insurers still classify as a lifestyle indication with limited or no coverage.
DCDC's billing team can verify your specific plan's coverage for either medication before your first prescription is issued, and documents the full clinical rationale — including blood work results — to support any pre-authorisation request. For a wider look at the full spectrum of medically supervised options beyond these two specific drugs, see our guide to medical weight loss options in Dubai, which covers coverage patterns across GLP-1 therapies, appetite-suppressing medications, and structured lifestyle programmes.
What to Expect at DCDC: Your Weight Management Journey
Whichever medication you and your doctor ultimately choose, the treatment pathway at Doctors Clinic Diagnostic Center (DCDC) follows a structured, evidence-based protocol built around thorough assessment before prescribing and precise monitoring during treatment.
Step 1: Initial Consultation and Assessment
Your first visit begins with a comprehensive medical history review and physical examination. Dr. Hadeel Elnur, who coordinates multi-specialty workups as patients' first point of contact, discusses weight history, previous weight loss attempts, current medications, dietary patterns, and any symptoms suggesting an underlying metabolic condition. This consultation is available from AED 299 at DCDC's location in Building 64, Block A, Al Razi Medical Complex, Dubai Healthcare City, with free parking and easy access roughly 10 minutes from Downtown Dubai.
Step 2: Same-Day Blood Work
On the same visit, DCDC's on-site laboratory draws blood for a comprehensive metabolic panel: fasting glucose, HbA1c, fasting insulin, a full thyroid panel, liver and kidney function markers, a lipid profile, and vitamin D levels. Because the lab is in-house, most results are available the same day, avoiding the multi-day wait common at clinics that outsource laboratory work.
Step 3: Prescription and Titration Plan
Once blood results are reviewed, the physician determines whether Mounjaro, Ozempic, or an alternative is most appropriate. You receive a personalised dose-titration schedule, injection technique instruction, dietary guidance emphasising protein intake for muscle preservation, and an exercise framework suited to your fitness level.
Monitoring and Follow-Up: Blood Tests and DEXA Scans
Ongoing monitoring is what separates responsible GLP-1 prescribing from simply handing out a medication. A DEXA body composition scan establishes a precise baseline for fat mass, lean muscle mass, and visceral fat before treatment starts, then is repeated periodically to confirm that weight loss is fat-dominant rather than muscle loss. This tracking approach mirrors the precision used in our DEXA body composition guide for athletes, applied here to weight management rather than performance training.
- Monthly visits: Weight measurement, side effect assessment, and dose adjustment during the titration phase
- Every 3 months: Repeat DEXA body composition scan plus a comprehensive metabolic blood panel
- 6-month review: Full reassessment of treatment goals, medication efficacy, and long-term plan
- Annual review: Complete metabolic workup comparable to the initial assessment
DCDC is open Saturday through Thursday from 8 AM to 10 PM and Friday from 9 AM to 9 PM, with a 4.8 out of 5 Google rating from over 1,000 verified patient reviews and a 98% patient satisfaction rate reflecting this thorough, follow-through-focused approach to care.
Dr. Hadeel's Clinical Perspective: Mounjaro or Ozempic?
Dr. Hadeel Elnur notes: "Patients in Dubai often walk in already having decided they want Mounjaro specifically because they've read it produces more weight loss on paper. That trial data is real, but it isn't the whole picture for an individual patient. Some people tolerate semaglutide's side effect profile better, some have insurance that only supports one option, and some simply respond better to one mechanism than the other for reasons we can't always predict in advance. My job is to start with a complete metabolic assessment — blood work and a DEXA scan — before recommending either medication, so the decision is based on your physiology, not on which name is trending online."
This evidence-first approach is consistent with MOHAP licensing standards and reflects why DCDC pairs every GLP-1 prescription with baseline and follow-up laboratory testing rather than issuing a prescription in isolation.
Which Is Right for You? A Decision Guide
Use this simple decision framework as a starting point for the conversation with your doctor — it is not a substitute for individual medical assessment.
- Do you have type 2 diabetes with an existing insurance approval pathway? If yes, Ozempic may be the more straightforward starting point.
- Is maximum average weight loss your top priority and can you accommodate the higher cost? If yes, Mounjaro's SURMOUNT trial data may make it the stronger option.
- Have you already tried semaglutide at its highest tolerated dose without reaching your goal? If yes, switching to Mounjaro's dual mechanism is a common next step.
- Are you highly sensitive to gastrointestinal side effects? If yes, a slower, more granular titration — often easier to individualise with Mounjaro's six dose strengths — may help, though either drug can be titrated cautiously.
- Is budget the primary constraint? If yes, Ozempic's typically lower monthly medication cost may make it more sustainable long-term.
Book Your GLP-1 Assessment at DCDC
Start with a comprehensive metabolic evaluation from AED 299. Same-day blood work, DEXA body composition scanning, and personalised treatment planning at a MOHAP-licensed facility in Dubai Healthcare City.
Direct billing with 20+ insurance providers including Daman, AXA, and Bupa.
Frequently Asked Questions
Below are the most common questions patients in Dubai ask when comparing Mounjaro and Ozempic.
Related Services at DCDC
Expert care and advanced diagnostics at Dubai Healthcare City
Endocrine & Metabolic Disorders
Metabolic assessment and medical weight management with GLP-1 therapy
Book AppointmentDEXA Body Composition
Track fat loss and muscle mass changes during weight loss treatment
Book AppointmentBlood Tests
Metabolic panels, HbA1c, thyroid, and hormone testing for weight management
Book AppointmentFrequently Asked Questions
Final Thoughts: Choosing Between Mounjaro and Ozempic in Dubai
Mounjaro and Ozempic represent two of the most effective medically supervised weight management tools available today, but they are not identical products competing on marketing alone. Mounjaro's dual GIP/GLP-1 mechanism is associated with greater average weight loss in trial data, while Ozempic offers a longer safety track record, a typically lower monthly cost, and often more established insurance pathways for patients with type 2 diabetes.
What both medications share is the need for proper medical supervision from start to finish. Neither should be prescribed without a thorough metabolic assessment, and neither produces optimal, sustainable results without ongoing monitoring of blood work and body composition. At DCDC in Dubai Healthcare City, every GLP-1 treatment pathway begins with comprehensive on-site blood work and a DEXA body composition scan to establish precise baselines, allowing us to confirm that treatment is producing healthy, fat-dominant weight loss rather than muscle loss.
If you are weighing Mounjaro against Ozempic, the most valuable first step is a consultation with a physician who evaluates your individual metabolic profile rather than simply prescribing whichever medication you ask for by name. At DCDC, that is exactly how every patient journey starts — with the data to make an informed decision.
Sources & References
This article was reviewed by our medical team and references the following sources:
- FDA - Approval of Mounjaro (tirzepatide) for Type 2 Diabetes
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 Trial). New England Journal of Medicine, 2022
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 Trial). New England Journal of Medicine, 2021
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2 Trial). New England Journal of Medicine, 2021
- European Medicines Agency (EMA) - Mounjaro Product Information
- Mayo Clinic - Tirzepatide (Subcutaneous Route)
- WHO - Obesity and Overweight Fact Sheet
Medical content on this site is reviewed by DHA-licensed physicians. See our editorial policy for more information.
Written by
Dr. Hadeel Elnur
General Practitioner
MD, General Practice
Dr. Hadeel Elnur is a General Practitioner at Doctors Clinic Diagnostic Center (DCDC) in Dubai Healthcare City.
Related Articles
Ozempic vs Wegovy Dubai: Differences (2026)
Ozempic Weight Loss Dubai: GLP-1 Guide (2026)
Medical Weight Loss Dubai: Options & Cost (2026)
Weight Loss Clinic Dubai: Options & Cost (2026)
DEXA Body Composition Dubai: Athletes Guide (2026)
More in Weight Loss
© 2026 Doctors Clinic Diagnostic Center (DCDC), Dubai Healthcare City. Originally published at https://doctorsclinicdubai.ae/blog/mounjaro-vs-ozempic-dubai. All rights reserved. Unauthorized reproduction is prohibited.